The Technology Is Ready. The Question Is Whether the Organization Is Governed to Use It.
For years, the case against AI in clinical development rested on the technology itself: models weren’t mature enough, data wasn’t structured enough, tools weren’t reliable enough. Those concerns were reasonable at the time, and they are becoming less relevant by the month. Modern AI systems can already analyze complex clinical information, flag inconsistencies, and accelerate review across the development lifecycle.
Yet many organizations are still stuck at the pilot stage, unable to move a promising proof-of-concept into something a validation team will actually rely on. The reason is rarely the model anymore. It’s that nobody has answered the governance questions a regulated environment requires before any tool touches submission-critical work.
What Governance Actually Requires Here
In most industries, “AI governance” means setting broad policy. In clinical development, it means something more specific and more testable:
- Sign-off authority. Who has the standing to accept an AI-generated table, listing, or figure as final, and what does that person need to see before they can do it?
- Change control. When the underlying model, prompt, or validation logic changes, is that treated as a controlled change with its own record, the way a SAS macro update would be?
- Audit ownership. If an inspector asks how a specific number was produced six months from now, whose job is it to reconstruct that answer, and how long does it take them?
- Role boundaries. Which decisions can an AI system make unsupervised (formatting checks, cross-table consistency), and which always require a named human reviewer (population definitions, endpoint interpretation)?
None of these are technology questions. They’re organizational design questions, and they have to be answered before an AI tool can be trusted with anything that reaches a regulatory submission. An organization that can’t answer them isn’t behind on AI. It’s behind on governance, which is a different and more fixable problem.
This Is Where Metadata and Leadership Meet
Our previous brief argued that AI is only as trustworthy as the metadata behind it, the source data, derivation logic, and assumptions that make a result explainable rather than just visible. That argument only holds if someone in the organization owns keeping that metadata layer intact as tools, teams, and processes change.
That’s a leadership function, not a technical one. Metadata maturity doesn’t happen because a platform supports it. It happens because someone was made accountable for it: who maintains the specification library, who decides when a derivation rule changes, who signs off when the metadata behind a result looks incomplete. Skip that ownership question and even the best-designed AI tool will drift out of sync with the specifications it’s supposed to trace back to.
Why Waiting Has a Cost
Some organizations are waiting for AI to mature further, for regulatory guidance to clarify, or simply to see what competitors do first. That caution is understandable given the stakes, but it isn’t free. Study complexity keeps growing, data volumes keep expanding, and timelines keep compressing regardless of when an organization decides to engage with AI governance.
The organizations that work out their sign-off authority, change control, and audit ownership now will be able to adopt each new AI capability faster than the ones still asking those questions for the first time when a regulator does. Governance built early is a one-time cost. Governance built under deadline pressure, after a tool is already in use, rarely holds up.
What Adoption Looks Like in Stages
Organizations that get this right tend not to flip a switch. A workable pattern looks something like this: a short pilot phase where the AI tool operates on one study with full human review of every output, a feedback period where the review team’s corrections get fed back into the governance rules themselves (not just the model), and only then a scaled rollout where routine outputs move through with lighter-touch review while judgment calls still route to a named reviewer. Each stage has a different answer to “who signs off on what,” and that’s the point. Governance that’s designed to evolve in steps is far more durable than governance written once and left untouched as usage scales.
The Real Question for Leadership
The question worth asking isn’t “are we ready for AI.” Vol. 4 of this series asked whether an organization could trace every number in its deliverables back to its source. This brief asks the harder companion question: if it can’t, whose job is it to fix that, and do they have the authority to do it?
Most organizations haven’t assigned that ownership yet. That gap, not model capability, is what will separate the organizations that scale AI safely from the ones that stall in pilot indefinitely, or worse, scale it without the accountability structure to catch a problem before a regulator does.
